ANT-GROUP
31.5.2022 08:34:04 CEST | Business Wire | Press release
Ant Group has been appointed as a member on the advisory committee of Elevandi, a company set up by the Monetary Authority of Singapore (MAS) with a mission to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy.
The advisory committee comprises senior leaders from eight organizations ranging from established financial institutions to Tech/FinTech players. Mr. Chen Leiming, Senior Vice President, who is responsible for Ant Group’s international public policy and government affairs, serves as the representative of Ant Group. Mr. Chen also oversees the legal, compliance, AML and privacy functions of Ant Group’s international businesses.
As an advisory committee member, Mr. Chen Leiming will represent Ant Group and involve in providing strategic guidance on:
- galvanising global conversations to shape FinTech industry agendas worldwide;
- identifying key structural trends and issues shaping the future of financial services; and
- fostering an open dialogue between policymakers and FinTech players on Fintech risks and opportunities.
Speaking on the appointment of Ant Group as an advisory committee member, Mr. Sopnendu Mohanty, Chairman of Elevandi’s Board of Directors and Chief FinTech Officer of MAS, said: “Elevandi's mission is to bring together the public and private sector to adopt technology and build the future of finance that is inclusive, impactful and sustainable. We welcome organisations that have shown passion and dedication in harnessing FinTech for the growth and development of the new digital economy to participate as advisory committee members.”
Mr. Chen Leiming, Senior Vice President, Ant Group, said: “It is a great honour to represent Ant Group and contribute to the mission of Elevandi which we share and resonate deeply. At Ant Group, we are committed to leveraging technology and knowledge to provide inclusive services to those unserved and underserved, and contribute to the society through initiatives such as Ant Forest to promote low carbon lifestyle, and 10x1000 Tech for Inclusion to bridge the global digital skills gap."
"We look forward to joining the fellow members of the advisory committee in furthering Elevandi’s efforts on cultivating a more inclusive, green, and sustainable fintech landscape for the future," Mr. Chen said.
As part of Ant Group’s participation in Elevandi, Mr. Douglas Feagin, Senior Vice President for Global Strategic Partnerships and Investments at Ant Group will attend Elevandi’s inaugural Point Zero Forum in Zurich as a speaker. Point Zero Forum is an invite-only, in-person gathering to frame new ideas in Web 3.0 and sustainable finance; develop new regulatory frameworks; and provide access to investment capital.
For more information on Elevandi and the full list of advisory committee members, please visit https://www.elevandi.io/media/company-set-up-by-mas-to-advance-fintech-announces-advisory-committee .
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.
Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.
For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
About Elevandi
Elevandi is set up by the Monetary Authority of Singapore (MAS) to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy. We work closely with governments, founders, investors, and corporate leaders to drive collaboration, education, and new sources of value at the industry and national levels. Our initiatives have convened over 300,000 people since 2016 to drive the growth of FinTech through events, closed-door roundtables, investor programmes, educational initiatives, and research.
We have built a coordinated set of consequential products that drive activity at the industry, national, regional and global level, which include:
- Singapore FinTech Festival (2-4 Nov 2022) , our annual flagship event for the global FinTech community.
- Point Zero Forum (21-23 June 2022), our invite only collaboration with the Switzerland government to convene leaders, investors and founders in Zurich.
- Elevandi Connects (7 July 2022), our programme and initiative to bring together early stage start-ups with leading investors and corporates to maximise commercial success in forging investment deals, co-innovation opportunities, and business partnerships.
- World FinTech Festival (July-Nov 2022), our partnerships with the public and private sectors in markets around the world.
- Green Shoots Series, our monthly event meetup which serves as a platform for public and private sector announcements and to discuss critical issues and opportunities in FinTech and the digital economy.
- Education initiatives, our certificates and mentoring programmes to upskill and reskill the global FinTech community in collaboration with Oxygen by APIX, academic and industry partners.
- Elevandi Forums, our purpose-driven roundtables aimed at bringing the public and private sectors together to advance developments and issues within the FinTech industry.
- Elevandi FinTech Insider Report , our reports on digital advancements for the global FinTech industry which synthesise knowledge from our activities with the public and private sectors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005477/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
